PERKINELMER INC Stock Price, News & Analysis

Oxford Immunotec, part of PerkinElmer, announced its T-SPOT® Discovery SARS-CoV-2 kit is utilized in the UK COVID-19 Human Challenge Study. This national collaboration aims to expedite vaccine development against COVID-19 by identifying effective viral doses in a controlled setting. The study began in March 2021, focusing on analyzing immune responses, particularly T cell reactions. The T-SPOT technology is employed to enhance understanding of immune responses, thus aiding future vaccine efficacy studies. The kit is currently for research use only.

PerkinElmer (NYSE: PKI) has agreed to acquire Immunodiagnostic Systems Holdings PLC (LSE: IHS) for about $155 million (£110 million), enhancing its diagnostics capabilities, particularly in immunodiagnostics. The deal, with an enterprise value of approximately $124 million (£88 million), is expected to close by early Q3 2021, pending shareholder and court approvals. This acquisition will integrate IDS's chemiluminescence products with PerkinElmer's offerings, creating synergies and expanding their global presence in key diagnostic markets.

PerkinElmer, Inc. (NYSE: PKI) has announced its agreement to acquire Nexcelom Bioscience for $260 million in cash, expected to close in Q2 2021. Nexcelom specializes in automated cell counting instruments and cytometry, generating approximately $40 million in 2021 revenues. This acquisition aims to enhance PerkinElmer's drug discovery solutions and streamline workflows for clients in academia and biopharmaceuticals. The deal follows PerkinElmer's recent acquisition of Horizon Discovery, indicating a strong push towards expanding capabilities in life sciences.

Oxford Immunotec, part of PerkinElmer, announced that its T-SPOT^®.COVID test will be utilized in the COV-AD study, collaborating with the University of Birmingham. This study aims to monitor the SARS-CoV-2 infection and immune responses in patients with antibody deficiencies. Conducted across 13 UK sites, it seeks to determine the outcomes of COVID-19 in immunodeficient patients by assessing their T cell responses and antibody levels. The results could inform vaccination strategies and improve the understanding of immunity in vulnerable populations.

PerkinElmer, a leading global innovator, is hosting a virtual Investor and Analyst Day on June 24, 2021, from 8:30 a.m. to 12:00 p.m. ET. This event will feature key presentations from the senior management team, including updates on current business conditions. Registered attendees can access a live webcast through the Investors section of the company's website. A replay will also be available post-event. In 2020, PerkinElmer reported revenues of approximately $3.8 billion and employs over 14,000 people globally.

PerkinElmer (NYSE: PKI) reported strong Q1 2021 results with GAAP earnings per share of $3.37, up from $0.30 in Q1 2020, and revenues of $1.308 billion, a significant increase from $652 million year-over-year. The operating income was $468 million, reflecting a profit margin of 35.8%. Diagnostics revenue soared 236% to $853 million. The company raised its 2021 revenue guidance to $4.37 billion, and EPS forecast to $7.77 for the year.

The Board of Directors of PerkinElmer declared a regular quarterly dividend of $0.07 per share on April 29, 2021. This dividend is set to be paid on August 6, 2021, to shareholders of record as of July 16, 2021.

PerkinElmer reported revenue of approximately $3.8 billion in 2020, boasting a workforce of around 14,000 employees across 190 countries. The company is a component of the S&P 500 Index.

Oxford Immunotec, part of PerkinElmer (NYSE: PKI), announced that its T-SPOT® Discovery SARS-CoV-2 kit will be used in the DIRECT study, which investigates immune responses to COVID-19 in ethnic minority healthcare workers. The study, funded by the National Core Studies group, aims to assess whether vaccination induces a T cell response, potentially revealing disparities in immune responses among different groups. The T-SPOT technology offers advantages over conventional antibody testing, providing critical insights into immunity and potential protection against infection.

Oxford Immunotec, part of PerkinElmer (NYSE: PKI), announced its T-SPOT® Discovery SARS-CoV-2 kit will be utilized in the UK Com-COV trial. This trial, led by the Oxford Vaccine Group, investigates immune responses from different COVID-19 vaccine combinations. Funded by the UK Vaccine Task Force, the trial's first phase has enrolled 830 participants and is expanding to include an additional 1,050. The goal is to evaluate how mixed vaccination schedules enhance immune responses, potentially providing longer-lasting protection against evolving virus variants.